Vistagen Therapeutics, Inc.
VTGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001411685
No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Vistagen Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +7 vs. Q2 2021
- Shares held
- 131.4M
- +8.21M (+6.7%) vs. Q2 2021
- Total value
- $360.2M
- −$27.9M (−7.2%) vs. Q2 2021
- New holders
- 18
- 35 more added
- Sold out
- 11
- 30 more reduced
3 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VTGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 48 | $2.54M |
| Q1 2026 | 56 | $8.12M |
| Q4 2025 | 55 | $8.84M |
| Q3 2025 | 58 | $81.8M |
| Q2 2025 | 51 | $30.3M |
| Q1 2025 | 48 | $39.0M |
| Q4 2024 | 54 | $44.9M |
| Q3 2024 | 47 | $45.3M |
| Q2 2024 | 43 | $56.3M |
| Q1 2024 | 42 | $90.8M |
| Q4 2023 | 46 | $90.0M |
| Q3 2023 | 34 | $15.7M |
| Q2 2023 | 33 | $1.82M |
| Q1 2023 | 83 | $4.79M |
| Q4 2022 | 86 | $4.15M |
| Q3 2022 | 93 | $9.13M |
| Q2 2022 | 112 | $122.1M |
| Q1 2022 | 116 | $167.8M |
| Q4 2021 | 106 | $269.2M |
| Q3 2021 | 105 | $360.2M |
| Q2 2021 | 101 | $389.0M |
| Q1 2021 | 74 | $225.2M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Vistagen Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Acuta Capital Partners, LLC | 11,728,033 | $32.1M | 11.44% | 00.0% | Unchanged |
| BlackRock Inc. | 11,748,472 | $32.2M | 0.00% | +98,454+0.8% | Added |
| OrbiMed Advisors LLC | 12,909,283 | $35.4M | 0.39% | −1,558,589−10.8% | Reduced |
| VR Adviser, LLC | 16,047,286 | $44.0M | 5.65% | 00.0% | Unchanged |
| NEA Management Company, LLC | 16,302,596 | $44.7M | 0.56% | 00.0% | Unchanged |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −165,645−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −157,000−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −102,641−100.0% | Sold out |
| ACT Capital Management, LLC | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| STRS Ohio | 0 | $0 | 0.00% | −44,300−100.0% | Sold out |
| Quantitative Systematic Strategies LLC | 0 | $0 | 0.00% | −29,289−100.0% | Sold out |
| Blair William & Co | 0 | $0 | 0.00% | −12,200−100.0% | Sold out |
| Xponance, Inc. | 0 | $0 | 0.00% | −10,473−100.0% | Sold out |
| Paradigm, Strategies in Wealth Management, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Atticus Wealth Management, LLC | 0 | $0 | 0.00% | −692−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −80−100.0% | Sold out |
| QS Investors, LLC | – | – | – | – | Not filed |
| M Holdings Securities, Inc. | – | – | – | – | Not filed |
| CWM, LLC | – | – | – | – | Not filed |